168 related articles for article (PubMed ID: 25126591)
21. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
22. Strategies to explore new approaches in the investigation and treatment of osteosarcoma.
Kim SY; Helman LJ
Cancer Treat Res; 2009; 152():517-28. PubMed ID: 20213413
[TBL] [Abstract][Full Text] [Related]
23. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
Weiss GJ; Byron SA; Aldrich J; Sangal A; Barilla H; Kiefer JA; Carpten JD; Craig DW; Whitsett TG
PLoS One; 2017; 12(6):e0179170. PubMed ID: 28586388
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
25. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients.
Subbiah V; Bupathi M; Kato S; Livingston A; Slopis J; Anderson PM; Hong DS
Oncoscience; 2015; 2(7):646-58. PubMed ID: 26328274
[TBL] [Abstract][Full Text] [Related]
26. Comparative genomic hybridization of low-grade central osteosarcoma.
Tarkkanen M; Böhling T; Gamberi G; Ragazzini P; Benassi MS; Kivioja A; Kallio P; Elomaa I; Picci P; Knuutila S
Mod Pathol; 1998 May; 11(5):421-6. PubMed ID: 9619593
[TBL] [Abstract][Full Text] [Related]
27. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.
Zhao J; Dean DC; Hornicek FJ; Yu X; Duan Z
Cancer Lett; 2020 Apr; 474():158-167. PubMed ID: 31987920
[TBL] [Abstract][Full Text] [Related]
28. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.
Hill KE; Kelly AD; Kuijjer ML; Barry W; Rattani A; Garbutt CC; Kissick H; Janeway K; Perez-Atayde A; Goldsmith J; Gebhardt MC; Arredouani MS; Cote G; Hornicek F; Choy E; Duan Z; Quackenbush J; Haibe-Kains B; Spentzos D
J Hematol Oncol; 2017 May; 10(1):107. PubMed ID: 28506242
[TBL] [Abstract][Full Text] [Related]
29. RUNX2 (6p21.1) amplification in osteosarcoma.
Gupta S; Ito T; Alex D; Vanderbilt CM; Chang JC; Islamdoust N; Zhang Y; Nafa K; Healey J; Ladanyi M; Hameed MR
Hum Pathol; 2019 Dec; 94():23-28. PubMed ID: 31669178
[TBL] [Abstract][Full Text] [Related]
30. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
Subbiah V; Westin SN; Wang K; Araujo D; Wang WL; Miller VA; Ross JS; Stephens PJ; Palmer GA; Ali SM
J Hematol Oncol; 2014 Jan; 7():8. PubMed ID: 24422672
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.
Pincez T; Clément N; Lapouble E; Pierron G; Kamal M; Bieche I; Bernard V; Fréneaux P; Michon J; Orbach D; Aerts I; Pacquement H; Bourdeaut F; Jiménez I; Thébaud E; Oudot C; Vérité C; Taque S; Owens C; Doz F; Le Tourneau C; Delattre O; Schleiermacher G
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896933
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
34. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
35. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
36. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
37. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
[TBL] [Abstract][Full Text] [Related]
38. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the osteosarcoma expression phenotype by microRNAs.
Namløs HM; Meza-Zepeda LA; Barøy T; Østensen IH; Kresse SH; Kuijjer ML; Serra M; Bürger H; Cleton-Jansen AM; Myklebost O
PLoS One; 2012; 7(10):e48086. PubMed ID: 23133552
[TBL] [Abstract][Full Text] [Related]
40. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.
Pishvaian MJ; Bender RJ; Halverson D; Rahib L; Hendifar AE; Mikhail S; Chung V; Picozzi VJ; Sohal D; Blais EM; Mason K; Lyons EE; Matrisian LM; Brody JR; Madhavan S; Petricoin EF
Clin Cancer Res; 2018 Oct; 24(20):5018-5027. PubMed ID: 29954777
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
